Aromatase inhibitors as adjuvant therapy for breast cancer

Journal of Clinical Oncology

Volumn 27, Issue 15, 2009, Pages 2566-2567

  Montemurro, Filippo ^a   Aglietta, Massimo ^a   Mastro, Lucia Del ^b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL TRIAL; ENDOMETRIUM CANCER; FOLLOW UP; HUMAN; LETTER; MONOTHERAPY; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOEMBOLISM; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; METHODOLOGY; NOTE;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS;

EID: 66349138501     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.2695     Document Type: Letter

References (23)

1. Seruga B, Tannock IF: Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: The emperor has no clothes. J Clin Oncol 27:840-842, 2009
2. Forbes JF, Cuzick J, Buzdar A, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
3. Coates AS, Keshaviah A, Thurlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007 (Pubitemid 350002953)
4. Boccardo F, Rubagotti A, Puntoni M, et al: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138-5147, 2005 (Pubitemid 46224022)
5. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
6. Jakesz R, Jonat W, Gnant M, et al: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462, 2005 (Pubitemid 41111693)
7. Jonat W, Gnant M, Boccardo F, et al: Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormonesensitive early-stage breast cancer: A meta-analysis. Lancet Oncol 7:991-996, 2006 (Pubitemid 44804137)
8. Mouridsen HT, Giobbie-Hurder A, Mauriac L, et al: BIG 1-98: a randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Cancer Res 69:66s, 2009 (suppl 2; abstr 13)
9. Northouse LL, Mood D, Kershaw T, et al: Quality of life of women with recurrent breast cancer and their family members. J Clin Oncol 20:4050-4064, 2002
10. Ravdin PM, Siminoff IA, Harvey JA: Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16:515-521, 1998
11. Fontaine C, Meulemans A, Huizing M, et al: Tolerance of adjuvant letrozole outside of clinical trials. Breast 17:376-381, 2008
12. Crew KD, Greenlee H, Capodice J, et al: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877-3883, 2007 (Pubitemid 47477264)
13. Evans L, Spelman M: The problem of non-compliance with drug therapy. Drugs 25:63-76, 1983
14. Kruse W, Rampmaier J, Ullrich G, et al: Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther 32:452-457, 1994 (Pubitemid 24277054)
15. Abramson N, Costantino JP, Garber JE, et al: Effect of factor V Leiden and prothrombin G20210->A mutations on thromboembolic risk in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention trial. J Natl Cancer Inst 98:904-910, 2006 (Pubitemid 44018920)
16. Cuzick J, Wale C: A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years treatment. Breast Cancer Res Treat 100:S24, 2006 (suppl 1; abstr 104)
17. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
18. Buzdar A, Howell A, Cuzick J, et al: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 7:633-643, 2006
19. Coleman RE, Banks LM, Girgis SI, et al: Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 8:119-127, 2007
20. Love CD, Muir BB, Scrimgeour JB, et al: Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 17:2050-2054, 1999
21. Gerber B, Krause A, Muller H, et al: Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound. J Clin Oncol 18:3464-3470, 2000 (Pubitemid 30783324)
22. Duffy SR, Distler W, Howell A, et al: A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. Am J Obstet Gynecol 200:80-87, 2009
23. North American Menopause Society: Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 13:340-367, 2006